GSK Acquires Global Rights to Janssen’s Hepatitis B Antiviral JNJ-3989 in $1 Billion Deal
GlaxoSmithKline (GSK; NYSE: GSK) has announced the acquisition of global rights to the hepatitis B...
Combination therapy
Seagen’s Adcetris Combo with Keytruda Shows Promising Results in Phase II Study
Seagen (NASDAQ: SGEN), currently in the process of being acquired by Pfizer (NYSE: PFE), has...
BMS and Karyopharm Partner to Evaluate Mezigdomide and Xpovio in Relapsed/Refractory Multiple Myeloma
Bristol Myers Squibb (BMS; NYSE: BMY) has entered into a collaboration and supply agreement with...
GSK’s ViiV Healthcare Secures NMPA Approval for Vocabria in HIV-1 Treatment
UK pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) has announced that its HIV joint venture, ViiV...
Jacobio Pharma’s Glecirasib Combo Shows Promising Results in ESMO Congress 2023 Presentation
China-based Jacobio Pharma (HKG: 1167) has presented clinical data for its KRAS G12C inhibitor glecirasib...
InxMed Presents Positive Data for FAK Inhibitor Ifebemtinib at ESMO 2023
China-based firm InxMed (Nanjing) Co., Ltd has updated two clinical studies for its first-in-class small-molecule...
Ascentage Pharma and AstraZeneca Expand Collaboration on CLL/SLL Treatment
China’s Ascentage Pharma (HKG: 6855) and UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) have entered...
Jiangsu Hengrui Licenses Camrelizumab-Apatinib Combo to Elevar Therapeutics
China-based pharmaceutical giant Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has signed a significant licensing...
FDA Approves Pfizer’s Braftovi + Mektovi Combo for BRAF V600E Metastatic NSCLC
The US Food and Drug Administration (FDA) has granted Pfizer (NYSE: PFE) regulatory approval for...
J&J’s Cetrelimab and TAR-200 Gain Tacit Approvals for Bladder Cancer Trials
The Center for Drug Evaluation (CDE) website has indicated that Johnson & Johnson (J&J; NYSE:...
Ascentage Pharma Initiates Phase III Study for APG-2575 and Calquence in CLL/SLL
Suzhou-based Ascentage Pharma (HKG: 6855) has announced the approval to commence a global multi-center, randomized,...
BioCity Biopharma Partners with AstraZeneca for Phase Ib/II Study in Hepatocellular Carcinoma
China-based biotech firm BioCity Biopharma has entered into a clinical study partnership with UK pharmaceutical...
RemeGen and Akeso Biopharma Initiate Phase II Study for Gastric Cancer Combo Therapy
China-based RemeGen Ltd (HKG: 9995) is poised to conduct a Phase II clinical study in...
Novartis’ Lutathera Meets Primary Endpoint in Phase III Trial for GEP-NETs
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that a Phase III trial for its...
Abbisko Therapeutics Gets NMPA Approval for Irpagratinib Combination Study in HCC
Shanghai-based biotechnology company Abbisko Therapeutics Co., Ltd (HKG: 2256) has received approval from the National...
Suzhou Zelgen Biopharmaceuticals’ ZG005 Receives NMPA Approval for Solid Tumor Trial
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a China-based pharmaceutical company, has announced that it...
AstraZeneca and Daiichi Sankyo Report Positive Results for Datopotamab Deruxtecan Combo in NSCLC
UK-based pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) has announced positive data from a Phase Ib...
Asieris Pharmaceuticals’ APL-1202 Shows Positive Interim Analysis in MIBC Trial with BeiGene’s Tislelizumab
China-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has revealed positive results from a Phase...
InnoCare Pharma and ArriVent Biopharma Partner on Clinical Study for Advanced NSCLC Treatment
China-based InnoCare Pharma (HKG: 9969; SHA: 688428) has announced that it has received the green...
Janssen Reports Positive Results from Phase Ib/II Study of Rybrevant Combo in EGFR-mutated NSCLC
Johnson & Johnson (J&J; NYSE: JNJ) subsidiary Janssen has provided an update on an ongoing...